

In collaboration with



Presented by



BEST OF ASCO®

OFFICIALLY LICENSED

19th - 20th August 2023
Indonesia

Co-host
















PHILIPPINE SOCIETY OF MEDICAL ONCOLOGY

Scientific Programme




Day 1 : 19th August 2023 | Saturday

Indonesian Time	Session Type	Title of Presentation	Speaker	Moderator/ Session Chair
12:00 - 12:05 Welcome Address				
12:05 - 12:25	Corporate Symposium 	Iceberg of early breast cancer (EBC) in Indonesia: What's the Unmet Needs?	 Trinugroho Heri Fadjar, Internist, Consultant Hematology-Medical Oncology (Bandung, Indonesia)	 Ary Harryanto Reksodiputro, Prof., PhD, Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)
12:25 - 13:20 Session 1 - Breast Cancer - Local & Metastatic				
12:25 - 12:35	Presentation	Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.	 Josephine Tolentino-Contreras, Internist, Consultant Medical Oncology (Manila, the Philippines)	
12:35 - 12:45	Presentation	Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.	 Hein Tay Zar Soe, MD, Consultant Medical Oncologist Moe Kaung Oncology Center (Yangon, Myanmar)	 C. Suharti, Prof., Internist, Consultant Hematology-Medical Oncology (Semarang, Indonesia)
12:45 - 12:55	Presentation	Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).	 Thurein Win, MD, Consultant Medical Oncologist Dept. of Medical Oncology, DSMA (Yangon, Myanmar)	
12:55 - 13:05	Presentation	Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.	 Khin Thin Mu, Prof., Consultant Medical Oncology, Yangon General Hospital - (Yangon, Myanmar)	
13:05 - 13:20 Panel Discussion & Q&A Session				
13:20 - 13:55 Session 2 - Central Nervous System Tumors				
13:20 - 13:30	Presentation	INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.	 Hilman Tadjoeidin, PhD, Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)	 Dini Andriani Pramitasari, Consultant Radiation Oncology, MPH (Jakarta, Indonesia)
13:30 - 13:40	Presentation	Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.	 Gregorius Ben Prayogi, MMedEd, Consultant Radiation Oncology (Jakarta, Indonesia)	
13:40 - 13:55 Panel Discussion & Q&A Session				
13:55 - 14:50 Session 3 - Developmental Therapy : Immunotherapy				

13:55 - 14:05	Presentation	Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.		Anna Mira Lubis, Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)	
14:05 - 14:15	Presentation	Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.		Pearla F. C. Lasut, Internist, Consultant Hematology-Medical Oncology (Manado, Indonesia)	
14:15 - 14:25	Presentation	Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.		Susanna Hilda Hutajulu, PhD, Internist, Consultant Hematology-Medical Oncology (Yogyakarta, Indonesia)	 Tubagus Djumhana Atmakusuma, PhD, Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)
14:25 - 14:35	Presentation	Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.		Macarena De La Fuente, Consultant Neuro-Oncology, Sylvester Comprehensive Cancer Center, Univ of Miami - (Miami, USA)	
14:35 - 14:50	Panel Discussion & Q&A Session				
14:50 - 14:55	Exhibition Tour Break				
14:55 - 15:15	Corporate Symposium 	Update Result of Trifluridine/Tipiracil Trials on Metastatic Colorectal Cancer Therapy		Eka W. Khorinal, Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)	 Ikhwan Rinaldi, PhD, MEd, Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)
15:15 - 16:20	Session 4 - Gastrointestinal Cancer				
15:15 - 15:25	Presentation	Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.		Yenny Dian Andayani, Internist, Consultant Hematology-Medical Oncology (Palembang, Indonesia)	
15:25 - 15:35	Presentation	PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).		Harvey Mamon, Prof., Gastrointestinal Radiation Oncology (Massachusetts, USA)	
15:35 - 15:45	Presentation	Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial.		Floris Verheij, MD, Department of Surgery Memorial Sloan Kettering Cancer Center (New York, USA)	 I Wayan Losen Adnyana, PhD, Internist, Consultant Hematology-Medical Oncology (Bali, Indonesia)
15:45 - 15:55	Presentation	Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.		Indra Wijaya, Internist, Consultant Hematology-Medical Oncology (Bandung, Indonesia)	
15:55 - 16:05	Presentation	Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.		Irza Wahid, Internist, Consultant Hematology-Medical Oncology (Padang, Indonesia)	
16:05 - 16:20	Panel Discussion & Q&A Session				

16:20 - 16:55

Session 5 - Genitourinary / Prostate

16:20 - 16:30	Presentation	TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.		Putu Niken , Internist, Consultant Hematology-Medical Oncology (Surabaya, Indonesia)		Johan Kurnianda , Internist, Consultant Hematology-Medical Oncology (Yogyakarta, Indonesia)
16:30 - 16:40	Presentation	Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.		Hein Myint Aung , Consultant Radiation Oncology - Moe Kaung Oncology Center (Yangon, Myanmar)		

16:40 - 16:55




Panel Discussion & Q&A Session

16:55 - 17:00

Exhibition Tour Break

17:00 - 17:35

Session 6 - GU - Kidney & Bladder




17:00 - 17:10	Presentation	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.		M. Riswan , Internist, Consultant Hematology-Medical Oncology (Banda Aceh, Indonesia)		Rainy T. Umbas , Prof., PhD, Consultant Oncology Urology (Jakarta, Indonesia)
17:10 - 17:20	Presentation	Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.		Nadia Ayu M. , Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)		

17:20 - 17:35

Panel Discussion & Q&A Session

17:35 - 18:10

Session 7 - Gynecologic Cancer




17:35 - 17:45	Presentation	Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/ RUBY).		Resti Mulya Sari , Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)		Abdul Muthalib, Prof. , Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)
17:45 - 17:55	Presentation	An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).		Marie Plante , Oncology Gynecologist - CHU de Quebec; LHotel-Dieu de Quebec (Quebec City, Canada)		

17:55 - 18:10

Panel Discussion & Q&A Session

18:10 - 18:45

Session 8 - Head and Neck Cancer




18:10 - 18:20	Presentation	Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.		Ari Rosenberg, PhD , Internist, Hematology and Medical Oncology (Chicago, USA)		Noorwati Sutandyo, Prof. , PhD, Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)
18:20 - 18:30	Presentation	Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.		Andhika Rachman, PhD , Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)		

18:30 - 18:45

Panel Discussion & Q&A Session

18:45 - 19:20

Session 9 - Leukemia

18:45 - 18:55	Presentation	Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).	 Muhammad Darwin Prenggono , Internist, Consultant Hematology-Medical Oncology (Banjarmasin, Indonesia)	 S. Ugroseno Yudho Bintoro, Prof., PhD , Internist, Consultant Hematology-Medical Oncology (Surabaya, Indonesia)
18:55 - 19:05	Presentation	Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.	 Cosphiadi Irawan , Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)	

19:05 - 19:20


Panel Discussion & Q&A Session

End of Day 1


Day 2 : 20th August 2023 | Sunday

Indonesian Time	Session Type	Title of Presentation	Speaker	Moderator/ Session Chair
Day 2 Opening Remarks from Committee Member				
10:00 - 10:55 Session 10 - Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Non-Small Cell Metastatic				
10:00 - 10:10	Presentation	KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.	 Heather Wakelee, Prof. , Internist Consultant of Oncology, Stanford Cancer Institute (California, USA)	 Ketut Suega, Prof., PhD , Internist, Consultant Hematology-Medical Oncology (Bali, Indonesia)
10:10 - 10:20	Presentation	OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIa NSCLC	 Aung Sann Oo, Prof. , - Dept. of Medical Oncology Mandalay General Hospital (Mandalay, Myanmar)	
10:20 - 10:30	Presentation	Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.	 James Chih-Hsin Yang , Consultant Medical Oncology- National Taiwan University Hospital (Taipei, Taiwan)	
10:30 - 10:40	Presentation	TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).	 Yasushi Goto, MD, PhD , Thoracic Oncology, National Cancer Center Hospital (Tokyo, Japan)	
10:40 - 10:55	Panel Discussion & Q&A Session			
10:55 - 11:50 Session 11 – Lymphoma / Plasma Cell Dyscrasias				
10:55 - 11:05	Presentation	Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.	 Eifel Faheri , Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)	 Ary Harryanto Reksodiputro, Prof., PhD , Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)
11:05 - 11:15	Presentation	Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.	 Shinta Oktya Wardhani , Internist, Consultant Hematology-Medical Oncology (Malang, Indonesia)	
11:15 - 11:30	Presentation	SWOG S1826, a Randomized Study of Nivolumab (N) AVD versus Brentuximab Vedotin (BV) AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma	 Pandji Irani Fianza, PhD , Internist, Consultant Hematology-Medical Oncology (Bandung, Indonesia)	
11:30 - 11:40	Presentation	Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.	 Tutik Harjianti , Internist, Consultant Hematology-Medical Oncology (Makassar, Indonesia)	

11:40 - 11:55	Q&A Session		
11:55 - 12:00	Exhibition Tour Break		
12:00 - 12:55	Session 12 – Melanoma / Skin Cancer/ Sarcoma		
12:00 - 12:10	Presentation	Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.	 <p>Jason Luke, PhD, Consultant Medical Oncology - UPMC Hillman Cancer Center / University of Pittsburgh (Pennsylvania, USA)</p>
12:10 - 12:20	Presentation	The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.	 <p>Sri Agustini Kurniawati, Internist, Consultant Hematology-Medical Oncology (Jakarta, Indonesia)</p>
12:20 - 12:30	Presentation	Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.	 <p>Soe Aung, Prof., PhD, Consultant Medical Oncologist (Yangon, Myanmar)</p>
12:30 - 12:40	Presentation	A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (AllianceA091902)	 <p>Myo Myint Maw, Prof., PhD, Consultant Medical Oncology (Yangon, Myanmar)</p>
12:40 - 12:55	Panel Discussion & Q&A Session		
12:55 - 13:30	Session 13 – Pediatric		
12:55 - 13:05	Presentation	Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621	 <p>Hikari Ambara Sjakti, PhD, Pediatric Consultant (Jakarta, Indonesia)</p>
13:05 - 13:15	Presentation	Genomic determinants of outcome in acute lymphoblastic leukemia: A Children's Oncology Group study	 <p>Murti Andriastuti, PhD, Pediatric Consultant (Jakarta, Indonesia)</p>
13:15 - 13:25	Panel Discussion & Q&A Session		
13:25 - 13:30	Exhibition Tour Break		
13:30 - 14:05	Session 14 – Symptom & Survivorship		
13:30 - 13:40	Presentation	A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.	 <p>Honey Sarita J. Abarquez, Internist, Medical Oncology Consultant (Davao City, The Philippines)</p>
13:40 - 13:50	Presentation	Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.	 <p>Jennifer Ligibel, Internist, Consultant Medical Oncology - Dana-Farber Cancer Institute (Boston, USA)</p>
13:50 - 14:05	Panel Discussion & Q&A Session		
14:05 - 14:25	Corporate Symposium 	ASTRUM-005: Serplulimab, A Novel Anti-PD-1 Antibody, Plus Chemotherapy versus Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: An International Randomized Phase 3 Study	 <p>Dr Hui Li (Changchun, China)</p>  <p>Sven Tang, MD (Singapore)</p>
14:25 - 14:30	Valedictory / Closing Remarks		



Andi Fachruddin Benyamin, PhD,
Internist, Consultant Hematology-Medical Oncology (Makassar, Indonesia)



Novie Amelia Choie, PhD,
Pediatric Consultant (Jakarta, Indonesia)



Nuzirwan Acang, Prof.,
Internist, Consultant Hematology-Medical Oncology (Cimahi, Indonesia)